These efforts led to the recent approval of the PARP inhibitor Olaparib for metastatic castrate-resistant prostate cancer patients with mutations in other HR genes besides BRCA1/2, increasing the percentage of patients with a potential predictive biomarker result who could benefit from that treatment [69, 72]. Here, BRCA1 is linked to prostate carcinoma.